BRIDGE-TIMI 73a Trial: Olezarsen significantly reduces triglyceride levels among patients with hypertriglyceridemia and elevated CV risk
Key Points: Olezarsen is an antisense oligonucleotide which targets messenger RNA for apolipoprotein C-III (APOC3), a lipoprotein which up-regulates triglyceride... Read more.
Mandibular Advancement Device (MAD) Therapy Non-Inferior to CPAP for Blood Pressure Reduction In OSA And High CV Risk: The CRESCENT Trial
Key Points: Hypertension (HTN) guidelines recommend treating obstructive sleep apnea (OSA) in such patients, though data on BP reduction for mandibular advancement... Read more.
Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Mellitus
Key Points: There is uncertainty determining who is likely to develop dysglycemia and type 2 diabetes mellitus (T2DM) due to weight gain and adiposity: 80% of those... Read more.
AEGIS-II: Apo A-I Infusions Did Not Reduce 90-Day MACE but Trended Towards Reduction in CV Death and MI
Key Points: Post-MI adverse cardiovascular events remain high despite robust evidence-based antiplatelet, statin, and anticoagulant therapy. Cholesterol efflux is... Read more.
Self-Expanding Evolut Valve non-inferior to Balloon-Expandable SAPIEN Valve in Severe Aortic Stenosis and Small Aortic Annuli
Key Points: The SMART trial is the first randomized non-inferiority trial to test a head-to-head comparison between the Medtronic Evolut valve (Evolut PRO/PRO+/FX)... Read more.
A single SC dose of Zilebesiran reduced systolic blood pressure in uncontrolled hypertension: KARDIA-2
Key Points: Zilebesiran is a subcutaneous injectable that targets hepatic angiotensinogen (AGT) synthesis by RNA interference. The KARDIA-1 trial showed that subcutaneous... Read more.
BE ACTIVE RCT: Financial incentive and gamification strategies borrowed from behavioral economics increased physical activity among adults at elevated ASCVD risk
Key Points: The majority of US adults at elevated risk for ASCVD do not engage in the recommended amount of daily exercise. Behavioral economic strategies to incentivize... Read more.
STEP-HFpEF DM TRIAL: Semaglutide improves HF-related symptoms and results in greater weight loss among patients with obesity-related HFpEF and type 2 DM
Key Points: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown to reduce body weight and improve HF-related symptoms among individuals... Read more.
Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome (TELE-ACS)
Key Points: TELE-ACS evaluates the use of telemedicine strategies to reduce hospital readmission rates in patients with a recent history of acute coronary syndrome ... Read more.
An “Inclisiran First” Strategy Shows Greater LDL-C Lowering Compared With Usual Care In Patients With ASCVD: The VICTORION-INITIATE Randomized Trial
Key Points: Most patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve sufficiently reduced low-density lipoprotein cholesterol (LDL-C) levels... Read more.
